Modular is seeking FDA clearance for its Pivot product.
10 reports, 2 independent
Updated Sep 3
Gone quiet
- Reports
- 10
- Developments
- 3
- Repetition
- 70%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Modular is seeking FDA clearance for its Pivot product.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA granted clearance for software enhancements to Modular's Pivot insulin delivery system.1 source
Modular filed for FDA clearance for its Pivot product.1 source
Modular Medical's Pivot product was showcased at a conference and received endorsements from Breakthrough T1D.1 source
Keep exploring
The entities involved
Related events
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA rule changes are causing delays in product approval, leading to the process exceeding Congressional mandated timeframes.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
Coverage
Newest first; wire copies grouped- dallassun.com
- ACCESS NewswireModular Medical Announces Completion of MODD1 Cartridge Production and Commencement of Pivot Conversion -More than 6,000 MODD1 cartridges produced - Conversion to Pivot-ready manufacturing in prepara
- ACCESS NewswireModular Medical Announces Next-Generation Pivot Insulin Pump at ADCES and Introduction of Level Ex Gamified Training Collaboration -Debuting a "coming soon" campaign for tubeless Pivot patch pump - E
- ACCESS NewswireModular Medical Announces MODD1 Cartridge Line Validated for Human-Use Production -Line has been in production at risk since early July - Production to continue until late August when conversion to P